Three VPC publications describe potential new therapeutics

13/09/17

Thee publications out of the VPC describing work towards the development of new therapeutics were published in the last week.

A study led by Drs. Michael Cox, Artem Cherkasov, and Paul Rennie is featured in a Sept. 6th news story from the Terry Fox Research Institute. Published in Oncotarget, the work describes a first-in-class small molecule targeting the DNA binding domain of the ETS-family transcription factor, ERG. The study shows that that disrupting ERG transcriptional activity is sufficient to suppress the major characteristics of ERG-transformed prostate cancers; this finding could help develop new therapeutic tools for men battling ERG-expressing metastatic castration-resistant prostate cancer.

A study led by Dr. Gleave is featured in a Sept. 11th Publications of the Week post by Science in the City.  The European Urology publication describes the evaluation of the novel drug darolutamide in preclinical models of prostate cancer and found that darolutamide delays growth of enzalutamide-resistant prostate cancer, in particular in cells with mutated forms of the androgen receptor after previous treatment. This data supports further evaluation of darolutamide in clinical trials.

A study lead by Dr. Zoubeidi was published on Sept. 12 in Clinical Cancer Research online. In this preclinical study, the group investigated molecular targets and therapeutics for PCS1, the most aggressive and lethal subtype of prostate cancer. They report that the Forkhead box M1 (FOXM1) pathway is the central driver of this subtype in enzalutamide castration-resistant prostate cancer, and targeting FOXM1 reduces cell growth and stemness. These preclinical results may guide clinical evaluation of targeting FOXM1 to eradicate highly aggressive and lethal PCS1 prostate cancer tumours.

News